Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
09:00am, Tuesday, 28'th Apr 2026
NEW YORK, April 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
SAN FRANCISCO, April 27, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBi
Important Information Regarding Section 20(a) Individual Liability Claims Important Information Regarding Section 20(a) Individual Liability Claims
Did you buy IBRX securities between January 19, 2026, and March 24, 202 6? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX) What: Securities fraud class action lawsuit filed Class
IBRX Global Rollout: EU, MENA, and Asia Shape 2026-27 Catalysts
01:36pm, Monday, 27'th Apr 2026
ImmunityBio's global push spans EU, MENA, and Asia, with early Saudi sales and key 2026 data readouts set to test demand and drive next growth phase.
IBRX: What Anktiva's Bladder Data Says About 2026 Sales
01:30pm, Monday, 27'th Apr 2026
ImmunityBio heads into 2026 riding Anktiva growth, but upcoming bladder trial data and broader use in earlier care will be key to sustaining momentum.
Is IBRX Priced for Perfection at Nearly 28x Forward Sales?
01:30pm, Monday, 27'th Apr 2026
ImmunityBio IBRX has delivered a stunning rerating in 2026. After a move like this, investors often stop debating the story and start debating the price.
What Makes ImmunityBio (IBRX) a New Buy Stock
01:02pm, Monday, 27'th Apr 2026
ImmunityBio (IBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New York, New York--(Newsfile Corp. - April 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors
09:00am, Monday, 27'th Apr 2026
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Sunday, 26'th Apr 2026
New class action for ImmunityBio (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/26/2026
New York, New York--(Newsfile Corp. - April 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19,
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline
10:50am, Saturday, 25'th Apr 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Did you buy IBRX securities between January 19, 2026, and March 24, 2026?
